1-5 of 5
Lothar Tremmel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Clinical Trials & Observations
Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, Robert K. Stuart, Michele Baccarani, Larry D. Cripe, Martin S. Tallman, Giovanna Meloni, Lucy A. Godley, Amelia A. Langston, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, Dan Douer, W. Wiktor-Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M. Bensen-Kennedy, Donald Small, B. Douglas Smith
Journal: Blood
Blood (2011) 117 (12): 3294–3301.
https://doi.org/10.1182/blood-2010-08-301796
Published: 2011
Journal Articles

Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis.

Bruce D. Cheson, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Richard H. van der Jagt, MD, Lothar Tremmel, PhD, Tal Zaks, MD
Journal: Blood
Blood (2009) 114 (22): 2681.
https://doi.org/10.1182/blood.V114.22.2681.2681
Published: 2009
Journal Articles

Are Patient or Disease Characteristics Associated with Complete Response or Progression During Bendamustine-Rituximab Treatment in Previously Treated Patients with Non-Hodgkin's Lymphoma?.

Mkaya Mwamburi, MD, PhD, Gayatri Ranganathan, MS, Debra Mayo, PharmD, MHA, Lothar Tremmel, PhD, Tal Z. Zaks, MD, PhD, Mathias J. Rummel, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 5002.
https://doi.org/10.1182/blood.V114.22.5002.5002
Published: 2009
Journal Articles

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R Baer, Alexander Perl, Steven Coutre, MD, Harry Erba, MD, Robert K Stuart, Michele Baccarani, MD, Larry D. Cripe, Martin S. Tallman, MD, Giovanna Meloni, Lucy A Godley, Amelia A Langston, MD, PhD, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, M.D., Dan Douer, Wieslaw W. Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M Bensen-Kennedy, Donald Small, B. Douglas Smith
Journal: Blood
Blood (2009) 114 (22): 788.
https://doi.org/10.1182/blood.V114.22.788.788
Published: 2009
Journal Articles

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Mark Levis, MD, PhD, B. Douglas Smith, MD, Miloslav Beran, MD, Maria R. Baer, MD, Harry P. Erba, MD, Larry Cripe, MD, Steven Coutre, MD, Anjali Advani, MD, Alexander Perl, MD, Marcel Devetten, MD, Robert Stuart, MD, Martin S. Tallman, MD, Peter Brown, PhD, Lothar Tremmel, Donald Small, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 403.
https://doi.org/10.1182/blood.V106.11.403.403
Published: 2005